Cosmetic Formulation Requirements (FD&C Act / MoCRA & ISO 22716)
Adequate Safety Substantiation (FD&C Act § 608 / MoCRA): Formulators must document robust scientific evidence—toxicological profiles, clinical safety assessments, published literature, or testing data—demonstrating that each ingredient and the finished formulation are safe under intended conditions of use before commercialization.
Prohibited and Restricted Substance Screening: Formulations must comply with restrictions under 21 CFR 700 (e.g., prohibition of bithionol, hexachlorophene, mercury compounds, chlorofluorocarbon propellants) and color additive approvals under 21 CFR 73/74/82.
Preservative Efficacy & Microbiological Control: Testing under USP <51> (Antimicrobial Effectiveness Testing) or ISO 11930 to confirm that the formulation maintains adequate antimicrobial preservation across its lifecycle.
Physical-Chemical & Packaging Compatibility: Formulation stability protocols (ISO/TR 18811) evaluating phase integrity, viscosity, pH, and absence of adverse interactions with primary container-closure systems under accelerated and real-time conditions.
Standardized Batch Records & Specifications (ISO 22716): Establishment of clear raw material acceptance criteria, finished-product release specifications, and locked master manufacturing formulas with explicit compounding instructions.
21 CFR Parts 210 & 211 Requirements (Pharmaceutical cGMP / OTC Drug-Cosmetics)
Applicable when a formulation carries an active drug claim or active pharmaceutical ingredient (e.g., sunscreens, anti-acne, anti-dandruff, antiperspirants).
Raw Material Testing and Quota Release (§ 211.84): Each lot of active pharmaceutical ingredient (API) and excipient must undergo identity testing and either complete laboratory testing or verified COA testing for purity, strength, and quality before release into formulation batching.
Master Production and Control Records (§ 211.186): Detailed, locked master formulas containing an accurate statement of the weight or measure of each ingredient, theoretical batch yields, calculation of excess/overage (if applicable), and step-by-step compounding procedures.
Written Processing & Process Validation (§ 211.100, § 211.110): Documented development of Critical Process Parameters (CPPs) such as heating/cooling rates, mixing speeds, addition sequences, and homogenization times to ensure in-process uniformity and batch-to-batch consistency.
Container-Closure Evaluation (§ 211.94): Primary packaging components must be evaluated to ensure they are non-reactive, non-additive, and non-absorptive, protecting the drug-cosmetic formulation against deterioration or contamination.
Formal Stability Programs & Expiration Dating (§ 211.137, § 211.166): Regulatory requirement to generate stability data using stability-indicating, validated analytical test methods across defined storage temperatures and humidity conditions to legally justify a finished product expiration date.
21 CFR Part 820 Requirements (Quality Management System Regulation / QMSR)
Historically the Quality System Regulation (QSR), now incorporating ISO 13485:2016 by reference. Applicable to medical devices and device-formulation combination products (e.g., topical wound dressings, ultrasound gels, delivery applicators).
Design and Development Planning (ISO 13485 Clause 7.3.2 / 21 CFR 820): Documented formulation development plans establishing project stages, design activities, team responsibilities, and resource allocation.
Design Inputs (ISO 13485 Clause 7.3.3): Defined, unambiguous technical inputs including intended use, target performance, chemical stability limits, biocompatibility requirements (ISO 10993), and user safety profiles.
Design Outputs (ISO 13485 Clause 7.3.4): Explicit formulation specifications, master recipe formulations, raw material acceptance thresholds, packaging specifications, and finished-product testing criteria that trace directly back to design inputs.
Design Verification (ISO 13485 Clause 7.3.6): Analytical, physical, and bench testing confirming that the formulation outputs meet all initial technical and input specifications (e.g., assays, viscosity, pH, barrier properties).
Design Validation (ISO 13485 Clause 7.3.7): Clinical, preclinical, or human factors testing ensuring the final formulation meets user needs and intended clinical utility under simulated or actual conditions of use.
Design Transfer (ISO 13485 Clause 7.3.8): Formal verification that the bench formulation is accurately translated into commercial production procedures, compounding batch records, and scalable manufacturing parameters.
Design History File / Medical Device File (ISO 13485 Clause 4.2.3 & 7.3.10 / § 820.35): Complete compilation of records demonstrating that the formulation was developed in strict accordance with the approved design plan and regulatory requirements.
ISO 9001:2015 Requirements (Quality Management Systems)
Applies to development processes to ensure consistent product delivery and customer/regulatory satisfaction.
Understanding Context and Scope (Clause 4): Identifying external regulatory mandates (MoCRA, REACH, FDA) and internal operational capabilities that govern formulation development.
Risk-Based Thinking (Clause 6.1): Proactive evaluation of technical formulation risks (e.g., raw material obsolescence, supplier single-sourcing, phase separation, chemical incompatibility) before advancing to pilot scale.
Design and Development Planning (Clause 8.3.2): Establishing milestones, design control stages, technical reviews, and validation gates throughout the formulation cycle.
Design and Development Inputs (Clause 8.3.3): Defining customer requirements, statutory/regulatory mandates, functional benchmarks, and historical performance criteria.
Design and Development Controls (Clause 8.3.4): Conducting systematic design reviews, verification runs (bench testing against specifications), and validation batches to confirm process capability.
Design and Development Outputs (Clause 8.3.5): Releasing locked formula bills of materials (BOM), manufacturing directions, inspection standards, and acceptance criteria suitable for production.
Control of Design Changes (Clause 8.3.6): Formal change control procedures governing any modifications to ingredients, supplier grades, or process parameters, ensuring changes are reviewed, verified, and approved prior to implementation.